CANF — Can Fite Biopharma Share News
0.000.00%
Last trade - 00:00- $4.92m
- $1.93m
- $0.41m
Brief: Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
Can-Fite Biopharma rises as liver disease drug shows potential as obesity treatment
Brief: Can Fite Biopharma Reports New Data On Namodenoson's Anti-Obesity Mechanism Of Action
Brief: Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
Brief: Can-Fite S Namodenoson For Treatment Of Pancreatic Cancer Patients Progress In Clinical Development
Brief: Can-Fite Announces Exercise Of Warrants For about $3.0 Million In Gross Proceeds
Brief: Can-Fite to Harness AI to Develop Novel Anti-Cancer Drugs
US-listed healthcare stocks fall amid Middle East conflict
Brief: Can-Fite To Share Its Rare Genetic Disease Lowe Syndrome Novel Treatment With Orphan Drug Japanese Companies
US-listed healthcare firms down amid Middle East conflict
Brief: Can-Fite Reports Second Quarter 2023 Financial Results
Plans To Develop Its Lead Drug Candidate, Piclidenoson, For Treatment Of Lowe Syndrome
Brief: Can-Fite Submitted FDA Pediatric Plan To Allow Registration Of Piclidenoson
Brief: Can-Fite Receives U.S. FDA Approval For Piclidenoson Psoriasis Registration Plan
Brief: Can-Fite To Submit Ind For The Treatment Of Pancreatic Cancer Patients With Namodenoson
Brief: Can-Fite Reports Q1 2023 Financial Results & Provides Clinical Update
Can Fite rises as pancreatic cancer drug shows results in pre-clinical study
Brief: Can Fite Biopharma Ltd's Drug Receives Recognition From American Society Of Clinical Oncology For Inhibition Of Pancreatic Cancer
Can-Fite BioPharma rises on plans to initiate cancer drug mid-stage trial